Click-based synthesis of triazolobithiazole Δf508-CFTR correctors for cystic fibrosis

Michael B. Donald; Kevin X. Rodriguez; Hannah Shay; Puay Wah Phuan; A. S. Verkman; Mark J. Kurth

doi:10.1016/j.bmc.2012.06.046

Click-based synthesis of triazolobithiazole Δf508-CFTR correctors for cystic fibrosis

Michael B. Donald, Kevin X. Rodriguez, Hannah Shay, Puay Wah Phuan, A. S. Verkman, Mark J. Kurth

Chemistry

Research output: Contribution to journal › Article

10 Scopus citations

Abstract

Copper catalyzed azide-alkyne cycloaddition (CuAAC) chemistry is reported for the construction of previously unknown 5-(1H-1,2,3-triazol-1-yl)-4,5′- bithiazoles from 2-bromo-1-(thiazol-5-yl)ethanones. These novel triazolobithiazoles are shown to have cystic fibrosis (CF) corrector activity and, compared to the benchmark bithiazole CF corrector corr-4a, improved log P values (4.5 vs 5.96).

Original language	English (US)
Pages (from-to)	5247-5253
Number of pages	7
Journal	Bioorganic and Medicinal Chemistry
Volume	20
Issue number	17
DOIs	https://doi.org/10.1016/j.bmc.2012.06.046
State	Published - Sep 1 2012

Fingerprint

Keywords

CF corrector
CuAAC
Cystic fibrosis
Triazolobithiazole

ASJC Scopus subject areas

Pharmaceutical Science
Drug Discovery
Organic Chemistry
Molecular Medicine
Molecular Biology
Clinical Biochemistry
Biochemistry

Cite this

Donald, M. B., Rodriguez, K. X., Shay, H., Phuan, P. W., Verkman, A. S., & Kurth, M. J. (2012). Click-based synthesis of triazolobithiazole Δf508-CFTR correctors for cystic fibrosis. Bioorganic and Medicinal Chemistry, 20(17), 5247-5253. https://doi.org/10.1016/j.bmc.2012.06.046

@article{2d2fef0e603b4e41940758d999b44735,

title = "Click-based synthesis of triazolobithiazole Δf508-CFTR correctors for cystic fibrosis",

abstract = "Copper catalyzed azide-alkyne cycloaddition (CuAAC) chemistry is reported for the construction of previously unknown 5-(1H-1,2,3-triazol-1-yl)-4,5′- bithiazoles from 2-bromo-1-(thiazol-5-yl)ethanones. These novel triazolobithiazoles are shown to have cystic fibrosis (CF) corrector activity and, compared to the benchmark bithiazole CF corrector corr-4a, improved log P values (4.5 vs 5.96).",

keywords = "CF corrector, CuAAC, Cystic fibrosis, Triazolobithiazole",

author = "Donald, {Michael B.} and Rodriguez, {Kevin X.} and Hannah Shay and Phuan, {Puay Wah} and Verkman, {A. S.} and Kurth, {Mark J.}",

year = "2012",

month = sep

day = "1",

doi = "10.1016/j.bmc.2012.06.046",

language = "English (US)",

volume = "20",

pages = "5247--5253",

journal = "Bioorganic and Medicinal Chemistry",

issn = "0968-0896",

publisher = "Elsevier Limited",

number = "17",

}

TY - JOUR

T1 - Click-based synthesis of triazolobithiazole Δf508-CFTR correctors for cystic fibrosis

AU - Donald, Michael B.

AU - Rodriguez, Kevin X.

AU - Shay, Hannah

AU - Phuan, Puay Wah

AU - Verkman, A. S.

AU - Kurth, Mark J.

PY - 2012/9/1

Y1 - 2012/9/1

N2 - Copper catalyzed azide-alkyne cycloaddition (CuAAC) chemistry is reported for the construction of previously unknown 5-(1H-1,2,3-triazol-1-yl)-4,5′- bithiazoles from 2-bromo-1-(thiazol-5-yl)ethanones. These novel triazolobithiazoles are shown to have cystic fibrosis (CF) corrector activity and, compared to the benchmark bithiazole CF corrector corr-4a, improved log P values (4.5 vs 5.96).

AB - Copper catalyzed azide-alkyne cycloaddition (CuAAC) chemistry is reported for the construction of previously unknown 5-(1H-1,2,3-triazol-1-yl)-4,5′- bithiazoles from 2-bromo-1-(thiazol-5-yl)ethanones. These novel triazolobithiazoles are shown to have cystic fibrosis (CF) corrector activity and, compared to the benchmark bithiazole CF corrector corr-4a, improved log P values (4.5 vs 5.96).

KW - CF corrector

KW - CuAAC

KW - Cystic fibrosis

KW - Triazolobithiazole

UR - http://www.scopus.com/inward/record.url?scp=84864984030&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84864984030&partnerID=8YFLogxK

U2 - 10.1016/j.bmc.2012.06.046

DO - 10.1016/j.bmc.2012.06.046

M3 - Article

C2 - 22841006

AN - SCOPUS:84864984030

VL - 20

SP - 5247

EP - 5253

JO - Bioorganic and Medicinal Chemistry

JF - Bioorganic and Medicinal Chemistry

SN - 0968-0896

IS - 17

ER -

Access to Document

10.1016/j.bmc.2012.06.046